{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:35:21Z","timestamp":1789504521824,"version":"build-2803163510"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background &amp; objectives:<\/jats:title>\n                    <jats:p>Mass Drug Administration (MDA) is one of the important pillars of eliminating lymphatic filariasis. The present study aimed to determine the pooled coverage and compliance of MDA and its determinants in the Southeast Asian regional countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This proposal was registered in PROSPERO. The study focused on four databases (PubMed, Scopus, Embase, and Cochrane Central) and articles published between January 2019 and March 2025. The setting was taken from studies performed across the Southeast Asian Region. Stata Version 17 was used for meta-analysis of the selected studies. The overall and subgroup-wise analysis was computed using the DerSimonian-Laird method for the random-effects model in Forest plots. A funnel plot was done to find out the publication bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Altogether, 34 articles were analysed. Of the 34 articles, 28 (82.3%) and 4 (11.8%) articles were published in India and Indonesia, respectively. The pooled coverage and compliance of MDA were found to be 80.16% (95% CI: 74.68-85.64%) and 67.25% (95% CI: 60.17-74.33%), respectively. Subgroup-wise, both coverage and compliance decreased in studies conducted in 2020 or afterwards. Side effects of the drugs, non-diseased status, suffering from some other diseases, too many drugs, bad taste of the drugs were some of the common barriers to successful MDA implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation &amp; conclusion:<\/jats:title>\n                    <jats:p>Thus, time has come to develop strategies to improve MDA coverage and compliance at the community level. The strategy would be bilateral, involving both providers and beneficiaries, who need to be engaged in the proper implementation of MDA administration at the grassroot level.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jvbd.jvbd_58_25","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:00:07Z","timestamp":1751515207000},"page":"27-35","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Coverage and determinants of Mass Drug Administration against lymphatic filariasis in Southeast Asian regional countries during the end-game strategy: A systematic review and meta-analysis"],"prefix":"10.4103","volume":"63","author":[{"given":"Indranil","family":"Saha","sequence":"first","affiliation":[{"name":"ICMR-National Institute for Research in Bacterial Infections, Kolkata, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR) Ghaziabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joydeep","family":"Majumder","sequence":"additional","affiliation":[{"name":"ICMR-Regional Medical Research Centre, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavani Shankara","family":"Bagepally","sequence":"additional","affiliation":[{"name":"Academy of Scientific and Innovative Research (AcSIR) Ghaziabad, India"},{"name":"ICMR-National Institute of Epidemiology, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepanjan","family":"Ray","sequence":"additional","affiliation":[{"name":"Neglected Tropical Diseases, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saibal","family":"Das","sequence":"additional","affiliation":[{"name":"ICMR-National Institute for Research in Bacterial Infections, Kolkata, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR) Ghaziabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kalita","sequence":"additional","affiliation":[{"name":"ICMR-Regional Medical Research Centre, NE, Dibrugarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Devaraja","sequence":"additional","affiliation":[{"name":"ICMR-Centre for Ageing and Mental Health, Salt Lake, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Velayudhan","sequence":"additional","affiliation":[{"name":"ICMR, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"Das","sequence":"additional","affiliation":[{"name":"ICMR-Centre for Ageing and Mental Health, Salt Lake, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Preventive & Social Medicine, All India Institute of Hygiene & Public Health, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjit","family":"Dey","sequence":"additional","affiliation":[{"name":"Department of Physiology, Centre for Nanoscience and Nanotechnology (CRNN) and Centre with Potential for Excellence in Particular Area (CPEPA), University of Calcutta, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"1","key":"R5-20260302","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/jfmpc.jfmpc_1149_22","article-title":"Coverage of mass drug administration (MDA) and operational issues in elimination of lymphatic filariasis in selected districts of Jharkhand, India","volume":"12","author":"Kumar","year":"2023","journal-title":"J Family Med Prim Care"},{"issue":"1","key":"R6-20260302","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cegh.2019.04.013","article-title":"Mass drug administration programme against lymphatic filariasis-an evaluation of coverage and compliance in a northern Karnataka district, India","volume":"8","author":"Kulkarni","year":"2020","journal-title":"Clin Epidemiol Glob Health"},{"issue":"9","key":"R7-20260302","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.4103\/jfmpc.jfmpc_503_19","article-title":"Coverage of mass drug administration for elimination of lymphatic filariasis in Urban Nagpur, Central India: A mixed method study","volume":"8","author":"Banerjee","year":"2019","journal-title":"J Family Med Prim Care"},{"issue":"9","key":"R8-20260302","doi-asserted-by":"crossref","first-page":"e0011588","DOI":"10.1371\/journal.pntd.0011588","article-title":"Coverage evaluation of mass drug administration with triple drug regimen in an evaluation unit in Nagpur district of Maharashtra, India","volume":"17","author":"Dinesh","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"R9-20260302","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/0972-9062.374034","article-title":"Coverage and compliance of mass drug administration (MDA) programme for elimination of lymphatic filariasis in an endemic district of eastern Uttar Pradesh, India","volume":"60","author":"Bashar","year":"2023","journal-title":"J Vector Borne Dis"},{"key":"R10-20260302","doi-asserted-by":"crossref","first-page":"1297954","DOI":"10.3389\/fphar.2024.1297954","article-title":"Factors influencing implementation of mass drug administration for lymphatic filariasis elimination: a mixed-method study in Odisha, India","volume":"15","author":"Ratna","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"R12-20260302","first-page":"1","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: What are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil Med Res"},{"issue":"2","key":"R13-20260302","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/ijph.ijph_312_23","article-title":"Acceptance of mass drug administration for prophylaxis against lymphatic filariasis in a tribal endemic area: A Descriptive Cross-sectional Study","volume":"68","author":"Agarwal","year":"2024","journal-title":"Indian J Public Health"},{"issue":"4","key":"R14-20260302","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/00494755221098532","article-title":"Mass drug administration for lymphatic filariasis elimination amidst COVID-19 pandemic in Odisha, India: A step towards achieving SDG-3","volume":"52","author":"Sinha","year":"2022","journal-title":"Trop Doct"},{"issue":"2","key":"R15-20260302","first-page":"118","article-title":"Coverage evaluation survey of Mass Drug Administration (mda) for elimination of lymphatic filariasis in Datia District of M.P","volume":"14","author":"Kumar","year":"2024","journal-title":"International Journal of Toxicological and Pharmacological Research"},{"key":"R16-20260302","doi-asserted-by":"crossref","DOI":"10.4103\/JVBD.jvbd_67_24","article-title":"Outcome Assessment of the implementation of mass drug administration against lymphatic filariasis, in Kalaburagi (Gulbarga) District of Karnataka state: A Cross Sectional Survey","author":"Babu","year":"2024","journal-title":"J Vector Borne Dis"},{"issue":"8","key":"R17-20260302","first-page":"76","article-title":"Coverage evaluation of mass drug administration of DEC for filariasis in Satna District","volume":"4","author":"Kumar","year":"2021","journal-title":"International Journal of Health and Clinical Research"},{"issue":"2","key":"R18-20260302","doi-asserted-by":"crossref","first-page":"170","DOI":"10.47203\/IJCH.2022.v34i02.007","article-title":"Coverage evaluation of Mass Drug Administration (MDA) for lymphatic filariasis in a district of Bundelkhand Region of Uttar Pradesh","volume":"34","author":"Barman","year":"2022","journal-title":"Indian J Community Health"},{"issue":"24","key":"R19-20260302","first-page":"2058","article-title":"Coverage and compliance of mass drug administration for elimination of lymphatic filariasis in a district of western Odisha, India","volume":"8","author":"Bhue","year":"2021","journal-title":"J Evid Based Med Healthc"},{"issue":"2","key":"R20-20260302","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3126\/jcmsn.v20i2.53615","article-title":"Coverage evaluation of mass drug administration for lymphatic fila-riasis in Mahoba District of Uttar Pradesh","volume":"20","author":"Kaushal","year":"2024","journal-title":"Journal of College of Medical Sciences-Nepal"},{"issue":"6","key":"R21-20260302","first-page":"164","article-title":"Assessment of mass drug administration activities for lymphatic filariasis elimination in Vizianagaram District of Andhra Pradesh","volume":"11","author":"Nayak","year":"2020","journal-title":"Indian J Public Health Res Dev"},{"issue":"6","key":"R22-20260302","first-page":"LC01","article-title":"Evaluation of triple drug administration for lymphatic filariasis in Prayagraj District, Uttar Pradesh, India: A cross-sectional study","volume":"17","author":"Parveen","year":"2023","journal-title":"Journal of Clinical and Diagnostic Research"},{"issue":"3","key":"R23-20260302","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.18203\/2394-6040.ijcmph20210843","article-title":"A study on coverage and compliance of mass drug administration for lymphatic filariasis in Prayagraj District, Uttar Pradesh, India","volume":"8","author":"Ram","year":"2021","journal-title":"Int J Community Med Public Health"},{"issue":"2","key":"R24-20260302","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/tp.tp_32_21","article-title":"Coverage and compliance of mass drug administration in lymphatic filariasis amidst the COVID-19 pandemic: A community based epidemiological study","volume":"12","author":"Chakraborty","year":"2022","journal-title":"Trop Parasitol"},{"issue":"2","key":"R25-20260302","first-page":"28","article-title":"Population based coverage survey results following Mass Drug Administration (MDA) against lymphatic filariasis in Baragarh District, Odisha","volume":"5","author":"Agrawal","year":"2023","journal-title":"International Journal of Academic Medicine and Pharmacy"},{"key":"R26-20260302","first-page":"57","article-title":"Effect of directly observed therapy (DOT) on Mass Drug Administration (MDA) coverage and status of Mass Drug Administration programme in Bankura district of West Bengal, India","volume":"18","author":"Haldar","year":"2019","journal-title":"IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN"},{"key":"R27-20260302","first-page":"40","article-title":"Coverage evaluation survey of mass drug administration strategy to eliminate lymphatic filariasis in north karnataka region. Are We on Track","volume":"8","author":"Gururaj","year":"2021","journal-title":"Annals of Community Health"},{"issue":"3","key":"R28-20260302","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.18203\/2394-6040.ijcmph20190618","article-title":"Evaluation of coverage, compliance of mass drug administration and assessment of awareness about lymphatic filariasis in Tikamgarh district of Madhya Pradesh: A cross sectional study","volume":"6","author":"Panika","year":"2019","journal-title":"Int J Community Med Public Health"},{"issue":"7","key":"R29-20260302","first-page":"15","article-title":"A cross - sectional study to evaluate mass drug administration for elimination of lymphatic filariasis in Bhandara district of Maharashtra","volume":"8","author":"Jadhao","year":"2019","journal-title":"GJRA - Global Journal for Research Analysis"},{"issue":"8","key":"R30-20260302","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.18203\/2394-6040.ijcmph20193492","article-title":"Evaluation of coverage and compliance to mass drug administration for lymphatic filariasis elimination in two endemic districts of Karnataka","volume":"6","author":"Shivalingaiah","year":"2019","journal-title":"Int J Community Med Public Health"},{"issue":"2","key":"R31-20260302","doi-asserted-by":"crossref","first-page":"265","DOI":"10.47203\/IJCH.2022.v34i02.022","article-title":"Evaluation of mass drug administration to eliminate lymphatic filariasis in Surguja and Surajpur District, Chhattisgarh","volume":"34","author":"Mendhe","year":"2022","journal-title":"Indian J Community Health"},{"issue":"4","key":"R32-20260302","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/mjhs.mjhs_22_22","article-title":"Coverage and compliance assessment survey following lymphatic filariasis mass drug administration in Warangal, Telangana","volume":"10","author":"Bhavani","year":"2022","journal-title":"MRIMS Journal of Health Sciences"},{"issue":"6","key":"R33-20260302","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4103\/jfmpc.jfmpc_1057_23","article-title":"Assessment of mass drug administration for lymphatic filariasis elimination in the Armori and Chamorshi blocks of Gadchiroli District, Maharashtra: A cross-sectional study","volume":"13","author":"Inkane","year":"2024","journal-title":"J Family Med Prim Care"},{"key":"R34-20260302","doi-asserted-by":"crossref","first-page":"101860","DOI":"10.1016\/j.cegh.2024.101860","article-title":"Mass drug administration to eliminate lymphatic filariasis: A population-based coverage and compliance study in Eastern India","volume":"30","author":"Mohanty","year":"2024","journal-title":"Clin Epidemiol Glob Health"},{"issue":"11","key":"R35-20260302","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010900","article-title":"Assessment of factors related to individuals who were never treated during mass drug administration for lymphatic filariasis in Ambon City, Indonesia","volume":"16","author":"Titaley","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"R36-20260302","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.5958\/0976-5506.2019.03799.9","article-title":"Evaluation of mass drug administration (A cross sectional study in Sanggu Village, South Barito, Central Kalimantan, Indonesia)","volume":"10","author":"Nurpila","year":"2019","journal-title":"Indian J Public Health Res Dev"},{"issue":"6-7","key":"R37-20260302","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/10105395231197916","article-title":"Factors Influencing drug compliance among adult with lymphatic filariasis in Indonesia: Findings from Nationwide Population-Based Health Survey","volume":"35","author":"Ipa","year":"2023","journal-title":"Asia Pac J Public Health"},{"issue":"3","key":"R38-20260302","doi-asserted-by":"crossref","first-page":"988","DOI":"10.5958\/0976-5506.2019.00631.4","article-title":"Community behavior towards filariasis mass drug administration in Tegaldowo village, Pekalongan distsrict, Indonesia","volume":"10","author":"Ginandjar","year":"2019","journal-title":"Indian J Public Health Res Dev"},{"issue":"3","key":"R39-20260302","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009002","article-title":"A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis","volume":"15","author":"Krentel","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"R40-20260302","doi-asserted-by":"crossref","DOI":"10.1186\/s13071-021-04583-y","article-title":"Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar","volume":"14","author":"Dickson","year":"2021","journal-title":"Parasit Vectors"},{"key":"R42-20260302","article-title":"Accelerated Plan for Elimination of Lymphatic Filariasis","year":"2018"},{"key":"R43-20260302","article-title":"LF Endemic Districts"},{"issue":"7","key":"R45-20260302","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/tropicalmed9070156","article-title":"Evaluation of mass drug administration coverage for lymphatic filariasis in the Lukonga Health Zone in 2022","volume":"9","author":"Ntumba","year":"2024","journal-title":"Tropical Medicine and Infectious Disease"},{"issue":"1","key":"R47-20260302","first-page":"7504871","article-title":"The Impact of mass drug administration on lymphatic filariasis","volume":"2022","author":"Aboagye","year":"2022","journal-title":"J Trop Med"},{"key":"R49-20260302","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2023","year":"2024","journal-title":"Weekly epidemiological record"},{"issue":"11","key":"R51-20260302","doi-asserted-by":"crossref","first-page":"e0008854","DOI":"10.1371\/journal.pntd.0008854","article-title":"A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018","volume":"14","author":"Willis","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"R52-20260302","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature","volume":"12","author":"Budge","year":"2018","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Journal of Vector Borne Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jvbd.jvbd_58_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:37:41Z","timestamp":1787773061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jvbd.jvbd_58_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jvbd.jvbd_58_25","relation":{},"ISSN":["0972-9062"],"issn-type":[{"value":"0972-9062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-03-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}